交易 Protagonist Therapeutics, Inc. - PTGX CFD
新增到我的最愛- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
- 所有權
交易條件
價差 | 0.07 | ||||||||
多頭倉位隔夜費用
多頭倉位隔夜費用
前往平台 | -0.026151% | ||||||||
空頭倉位隔夜費用
空頭倉位隔夜費用
前往平台 | 0.003929% | ||||||||
隔夜費時間 | 21:00 (UTC) | ||||||||
最小成交量 | 1 | ||||||||
貨幣 | USD | ||||||||
保證金 | 5% | ||||||||
股票交易 | United States of America | ||||||||
交易委員會 | 0% |
*Information provided by Capital.com
Protagonist Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Sep 26, 2023 | 17.45 | 0.29 | 1.69% | 17.16 | 18.14 | 17.16 |
Sep 25, 2023 | 17.17 | 0.38 | 2.26% | 16.79 | 17.17 | 16.37 |
Sep 22, 2023 | 17.08 | 0.53 | 3.20% | 16.55 | 17.12 | 16.52 |
Sep 21, 2023 | 16.92 | 0.16 | 0.95% | 16.76 | 17.01 | 16.49 |
Sep 20, 2023 | 16.97 | -0.43 | -2.47% | 17.40 | 17.75 | 16.92 |
Sep 19, 2023 | 17.63 | 0.15 | 0.86% | 17.48 | 17.87 | 17.42 |
Sep 18, 2023 | 17.60 | -0.11 | -0.62% | 17.71 | 17.97 | 17.54 |
Sep 15, 2023 | 17.85 | -0.12 | -0.67% | 17.97 | 18.03 | 17.32 |
Sep 14, 2023 | 17.95 | -0.27 | -1.48% | 18.22 | 18.59 | 17.82 |
Sep 13, 2023 | 18.41 | -0.06 | -0.32% | 18.47 | 18.84 | 18.39 |
Sep 12, 2023 | 18.78 | 0.05 | 0.27% | 18.73 | 19.11 | 18.63 |
Sep 11, 2023 | 18.83 | -0.12 | -0.63% | 18.95 | 18.99 | 18.58 |
Sep 8, 2023 | 19.00 | 0.53 | 2.87% | 18.47 | 19.07 | 18.47 |
Sep 7, 2023 | 18.70 | -0.82 | -4.20% | 19.52 | 19.53 | 18.69 |
Sep 6, 2023 | 19.75 | 0.39 | 2.01% | 19.36 | 19.79 | 19.10 |
Sep 5, 2023 | 19.54 | 0.03 | 0.15% | 19.51 | 19.85 | 19.12 |
Sep 1, 2023 | 19.49 | -0.34 | -1.71% | 19.83 | 20.18 | 19.41 |
Aug 31, 2023 | 19.78 | 0.30 | 1.54% | 19.48 | 20.26 | 19.48 |
Aug 30, 2023 | 19.89 | -0.09 | -0.45% | 19.98 | 20.26 | 19.58 |
Aug 29, 2023 | 20.20 | 0.23 | 1.15% | 19.97 | 20.43 | 19.97 |
Protagonist Therapeutics, Inc. Events
时间(协调世界时) (UTC) | 國家 | 事件 |
---|---|---|
Monday, November 6, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 國家 US
| 事件 Q3 2023 Protagonist Therapeutics Inc Earnings Release Q3 2023 Protagonist Therapeutics Inc Earnings ReleaseForecast(預報) -上一頁 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
總營業費用 | 157.954 | 153.202 | 93.729 | 80.752 | 73.194 |
銷售/一般/行政費用,總計 | 31.739 | 27.196 | 18.638 | 15.749 | 13.697 |
研究與開發 | 126.215 | 126.006 | 74.506 | 65.003 | 59.497 |
營業收入 | -131.373 | -125.845 | -65.101 | -80.521 | -42.269 |
利息收入(費用),非經營淨值 | 4.06 | 0.443 | 0.302 | 2.644 | 2.546 |
其他,淨值 | -0.08 | -0.149 | -0.046 | -0.001 | 0 |
稅前淨收入 | -127.393 | -125.551 | -64.845 | -77.878 | -39.723 |
稅後淨收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
未計算非常項目前的淨收益 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
淨收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Total Adjustments to Net Income | 0 | ||||
普通股股東可獲收益 (不含非經常性項目) | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
普通股股東可獲收益 (含非經常性項目) | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
攤薄淨收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
攤薄後加權平均股 | 49.0422 | 46.3229 | 34.3965 | 25.894 | 22.3645 |
扣除特別項目的每股攤薄盈利 | -2.59762 | -2.71034 | -1.92316 | -2.98088 | -1.74044 |
每股正常攤薄盈利 | -2.59762 | -2.71034 | -1.91211 | -2.98088 | -1.74044 |
收入 | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
非常規項目總計 | |||||
Dividends per Share - Common Stock Primary Issue | 0 | ||||
異常費用(收入) | 0 | 0 | 0.585 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 0 | 0 | 0 | 0 | 0.859 |
收入 | 0 | 0 | 0 | 0 | 0.859 |
總營業費用 | 42.354 | 36.021 | 36.516 | 32.303 | 42.302 |
銷售/一般/行政費用,總計 | 9.172 | 8.605 | 6.632 | 6.901 | 7.691 |
研究與開發 | 33.182 | 27.416 | 29.884 | 25.402 | 34.611 |
營業收入 | -42.354 | -36.021 | -36.516 | -32.303 | -41.443 |
利息收入(費用),非經營淨值 | 3.913 | 2.491 | 2.251 | 1.157 | 0.484 |
其他,淨值 | -0.019 | -0.195 | 0.071 | -0.086 | -0.078 |
稅前淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
稅後淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
未計算非常項目前的淨收益 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
普通股股東可獲收益 (不含非經常性項目) | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
普通股股東可獲收益 (含非經常性項目) | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
攤薄淨收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
攤薄後加權平均股 | 56.7757 | 50.5737 | 49.2549 | 49.1076 | 49.0499 |
扣除特別項目的每股攤薄盈利 | -0.6774 | -0.66685 | -0.69422 | -0.63599 | -0.83664 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.6774 | -0.66685 | -0.69422 | -0.63599 | -0.83664 |
異常費用(收入) | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 243.077 | 340.736 | 315.606 | 145.311 | 137.503 |
現金和短期投資 | 237.355 | 326.9 | 305.809 | 133.017 | 128.853 |
現金等價物 | 125.744 | 123.665 | 117.358 | 33.006 | 82.233 |
短期投資 | 111.611 | 203.235 | 188.451 | 100.011 | 46.62 |
應收賬款總額,淨額 | 0.052 | 5.333 | 3.821 | 7.499 | 6.511 |
預付的費用 | 5.67 | 8.503 | 5.966 | 4.785 | 2.129 |
其他流動資産,總計 | 0.01 | 0.01 | 0.01 | ||
總資産 | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
物業/廠房/設備,總計 - 淨額 | 4.626 | 6.734 | 6.412 | 7.723 | 0.861 |
物業/廠房/設備,總計 - 總額 | 9.88 | 10.992 | 9.885 | 10.364 | 2.938 |
累計折舊,總計 | -5.254 | -4.258 | -3.473 | -2.641 | -2.077 |
長期投資 | 2 | ||||
其他長期資産,總計 | 0.225 | 0.225 | 0.45 | 1.883 | 1.108 |
流動負債總額 | 31.179 | 44.016 | 40.241 | 35.406 | 26.158 |
應付賬款 | 3.64 | 1.6 | 3.075 | 2.79 | 5.711 |
Payable/Accrued | |||||
預提費用 | 27.055 | 39.509 | 19.875 | 13.494 | 11.068 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
負債總額 | 32.32 | 47.674 | 44.862 | 74.953 | 26.957 |
長期債務總額 | 0 | 0 | 0 | 9.794 | 0 |
長期債務 | 0 | 9.794 | |||
總權益 | 215.608 | 300.021 | 279.606 | 79.964 | 112.515 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
普通股 | 0.00049 | 0.00048 | 0.00044 | 0.00027 | 0 |
額外實收資本 | 752.722 | 709.682 | 563.389 | 297.846 | 253.222 |
留存收益(累計赤字) | -536.755 | -409.362 | -283.811 | -217.661 | -140.474 |
其他權益,總計 | -0.35949 | -0.29948 | 0.02756 | -0.22127 | -0.233 |
總負債和股東權益 | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
已發行普通股總數 | 49.3392 | 47.8383 | 43.7455 | 27.2176 | 23.1872 |
其他流動負債,總計 | 0.484 | 2.907 | 17.291 | 19.122 | 9.379 |
其他負債,總計 | 1.141 | 3.658 | 4.621 | 29.753 | 0.799 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流動資産總額 | 235.736 | 243.077 | 276.617 | 304.302 | 341.522 |
現金和短期投資 | 230.759 | 237.355 | 267.437 | 291.89 | 305.289 |
現金等價物 | 127.686 | 125.744 | 152.816 | 120.237 | 98.477 |
短期投資 | 103.073 | 111.611 | 114.621 | 171.653 | 206.812 |
應收賬款總額,淨額 | 0.051 | 0.052 | 0.62 | 3.363 | 28.504 |
預付的費用 | 4.926 | 5.67 | 8.56 | 9.049 | 7.729 |
總資産 | 239.858 | 247.928 | 282.174 | 310.512 | 348.296 |
物業/廠房/設備,總計 - 淨額 | 3.897 | 4.626 | 5.332 | 5.985 | 6.549 |
長期投資 | |||||
其他長期資産,總計 | 0.225 | 0.225 | 0.225 | 0.225 | 0.225 |
流動負債總額 | 23.229 | 31.179 | 36.754 | 40.088 | 43.456 |
應付賬款 | 4.021 | 3.64 | 4.715 | 1.412 | 7.159 |
預提費用 | 18.852 | 27.055 | 31.816 | 38.336 | 34.995 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 0.356 | 0.484 | 0.223 | 0.34 | 1.302 |
負債總額 | 23.691 | 32.32 | 38.558 | 42.534 | 46.518 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
其他負債,總計 | 0.462 | 1.141 | 1.804 | 2.446 | 3.062 |
總權益 | 216.167 | 215.608 | 243.616 | 267.978 | 301.778 |
普通股 | 0.001 | 0.00049 | 0.00049 | 0.00049 | 0.00049 |
額外實收資本 | 786.768 | 752.722 | 746.657 | 740.027 | 732.542 |
留存收益(累計赤字) | -570.48 | -536.755 | -502.561 | -471.329 | -430.292 |
其他權益,總計 | -0.122 | -0.35949 | -0.48049 | -0.72049 | -0.47249 |
總負債和股東權益 | 239.858 | 247.928 | 282.174 | 310.512 | 348.296 |
已發行普通股總數 | 51.4405 | 49.3392 | 49.1984 | 48.6839 | 48.5521 |
其他流動資産,總計 | |||||
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
物業/廠房/設備,總計 - 總額 | 9.389 | 9.88 | 10.302 | 10.721 | 11.074 |
累計折舊,總計 | -5.492 | -5.254 | -4.97 | -4.736 | -4.525 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
淨收入/起跑線 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
經營活動産生的現金 | -108.137 | -107.865 | -72.484 | -41.527 | -49.947 |
經營活動産生的現金 | 1.034 | 0.813 | 0.789 | 0.703 | 0.527 |
非現金物品 | 25.988 | 20.187 | 10.455 | 9.588 | 7.125 |
營運資金的變化 | -7.766 | -3.314 | -19.016 | 26.144 | -18.017 |
投資活動産生的現金 | 91.468 | -15.86 | -90.965 | -53.71 | 2.213 |
資本支出 | -0.795 | -1.101 | -0.471 | -0.967 | -0.486 |
其他投資現金流量項目,總計 | 92.263 | -14.759 | -90.494 | -52.743 | 2.699 |
融資活動産生的現金 | 18.838 | 129.923 | 247.626 | 46.036 | 24.115 |
股票的發行(報廢),淨額 | 19.001 | 130.112 | 258.164 | 36.271 | 24.115 |
外彙效應 | -0.09 | -0.126 | 0.175 | -0.026 | -0.177 |
現金淨變化 | 2.079 | 6.072 | 84.352 | -49.227 | -23.796 |
Deferred Taxes | 0 | 1.438 | -0.775 | -0.658 | |
Cash Taxes Paid | 0 | 0 | 0.438 | 0.07 | |
債務的發行(退還),淨額 | 0 | -10.524 | 9.765 | ||
融資現金流項目 | -0.163 | -0.189 | -0.014 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -33.725 | -127.393 | -93.199 | -61.967 | -20.93 |
Cash From Operating Activities | -34.347 | -108.137 | -76.502 | -51.301 | -37.666 |
Cash From Operating Activities | 0.248 | 1.034 | 0.778 | 0.508 | 0.249 |
Non-Cash Items | 7.107 | 25.988 | 20.806 | 14.362 | 6.877 |
Changes in Working Capital | -7.977 | -7.766 | -4.887 | -4.204 | -23.862 |
Cash From Investing Activities | 9.826 | 91.468 | 87.533 | 30.258 | -4.476 |
Capital Expenditures | -0.01 | -0.795 | -0.725 | -0.563 | -0.273 |
Other Investing Cash Flow Items, Total | 9.836 | 92.263 | 88.258 | 30.821 | -4.203 |
Cash From Financing Activities | 26.463 | 18.838 | 18.285 | 17.605 | 16.925 |
Financing Cash Flow Items | -0.1 | -0.163 | -0.163 | -0.161 | -0.186 |
Issuance (Retirement) of Stock, Net | 26.563 | 19.001 | 18.448 | 17.766 | 17.111 |
Foreign Exchange Effects | 0 | -0.09 | -0.165 | 0.01 | 0.029 |
Net Change in Cash | 1.942 | 2.079 | 29.151 | -3.428 | -25.188 |
Deferred Taxes | 0 | ||||
Issuance (Retirement) of Debt, Net | 0 | ||||
Cash Taxes Paid | 0 |
差價合約交易計算器
計算您的假設損益
交易佣金
0
- 1:1
槓桿
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
打開
關閉
做空 做多
Industry: | Biotechnology & Medical Research (NEC) |
7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US
收入報表
- Annual
- Quarterly
人們也觀看
還在尋找值得信賴的經紀商?
加入全球 555.000 多名交易者,選擇與 Capital.com 交易